Evaluating efficacy of pharmaceutical interventions in atherosclerosis: Role of magnetic resonance imaging and positron emission tomography

Mount Sinai Journal of Medicine

Volumn 79, Issue 6, 2012, Pages 689-704

  Hyafil, Fabien ^a,b   Feldman, Laurent ^a,b   Le Guludec, Dominique ^a,b   Fayad, Zahi A ^c  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; high risk plaque; magnetic resonance imaging; pharmaceutical interventions; positron emission tomography

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; ATORVASTATIN; C REACTIVE PROTEIN; DALCETRAPIB; GADOLINIUM CHELATE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROBUCOL; SIMVASTATIN; STATIN (PROTEIN); ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; CHOLESTEROL DIET; DISEASE COURSE; DRUG EFFICACY; DRUG UPTAKE; ENDARTERECTOMY; GLUCOSE BLOOD LEVEL; HISTOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; MACROPHAGE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT DURATION; ZYMOGRAPHY;

ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; DRUG MONITORING; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 84871304087     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.21349     Document Type: Review

References (99)

1. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104: 2746-2753.
2. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-1375.
3. Davies MJ, Thomas A., Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-1140.
4. Falk E, Shah PK, Fuster V., Coronary plaque disruption. Circulation 1995; 92: 657-671.
5. Fuster V, Fayad ZA, Badimon JJ., Acute coronary syndromes: biology. Lancet 1999; 353 (suppl 2): SII5-SII9.
6. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005; 46: 937-954.
7. Ross R., Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
8. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003; 108: 1664-1672.
9. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002; 106: 804-808.
10. Mauriello A, Sangiorgi G, Fratoni S, et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 2005; 45: 1585-1593.
11. Fuster V, Fayad ZA, Moreno PR, et al. Atherothrombosis and high-risk plaque: part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol 2005; 46: 1209-1218.
12. Kastelein JJ, de Groot E., Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J 2008; 29: 849-858.
13. Nicholls SJ, Sipahi I, Schoenhagen P, et al. Application of intravascular ultrasound in anti-atherosclerotic drug development. Nat Rev Drug Discov 2006; 5: 485-492.
14. Fayad ZA, Fallon JT, Shinnar M, et al. Noninvasive in vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. Circulation 1998; 98: 1541-1547.
15. Fayad ZA, Nahar T, Fallon JT, et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation 2000; 101: 2503-2509.
16. Fayad ZA, Fuster V, Fallon JT, et al. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation 2000; 102: 506-510.
17. Achenbach S, Raggi P., Imaging of coronary atherosclerosis by computed tomography. Eur Heart J 2010; 31: 1442-1448.
18. Inoue K, Motoyama S, Sarai M, et al. Serial coronary CT angiography-verified changes in plaque characteristics as an end point: evaluation of effect of statin intervention. JACC Cardiovasc Imaging 2010; 3: 691-698.
19. Brenner DJ, Shuryak I, Einstein AJ., Impact of reduced patient life expectancy on potential cancer risks from radiologic imaging. Radiology 2011; 261: 193-198.
20. Helft G, Worthley SG, Fuster V, et al. Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. Circulation 2002; 105: 993-998.
21. Corti R, Osende JI, Fallon JT, et al. The selective peroxisomal proliferator-activated receptor-γ agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J Am Coll Cardiol 2004; 43: 464-473.
22. Corti R, Osende J, Hutter R, et al. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis 2007; 190: 106-113.
23. Viles-Gonzalez JF, Fuster V, Corti R, et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study. Eur Heart J 2005; 26: 1557-1561.
24. Giannarelli C, Cimmino G, Connolly TM, et al. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: a magnetic resonance imaging study in a model of advanced atherosclerosis. Eur Heart J 2012; 33: 264-273.
25. Ibanez B, Vilahur G, Cimmino G, et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol 2008; 51: 1104-1109.
26. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-2300.
27. Corti R, Fuster V, Fayad ZA, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002; 106: 2884-2887.
28. Yonemura A, Momiyama Y, Fayad ZA, et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 2005; 45: 733-742.
29. El Aidi H, Mani V, Weinshelbaum KB, et al. Cross-sectional, prospective study of MRI reproducibility in the assessment of plaque burden of the carotid arteries and aorta. Nat Clin Pract Cardiovasc Med 2009; 6: 219-228.
30. Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005; 46: 106-112.
31. Fayad ZA, Mani V, Woodward M, et al. dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378: 1547-1559.
32. Fayad ZA, Fuster V., Characterization of atherosclerotic plaques by magnetic resonance imaging. Ann N Y Acad Sci 2000; 902: 173-186.
33. Yuan C, Mitsumori LM, Beach KW, et al. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiology 2001; 221: 285-299.
34. Yuan C, Mitsumori LM, Ferguson MS, et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation 2001; 104: 2051-2056.
35. Yuan C, Zhang SX, Polissar NL, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 2002; 105: 181-185.
36. Chu B, Kampschulte A, Ferguson MS, et al. Hemorrhage in the atherosclerotic carotid plaque: a high-resolution MRI study. Stroke 2004; 35: 1079-1084.
37. Burke AP, Farb A, Malcom GT, et al. Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA 1999; 281: 921-926.
38. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-2325.
39. Takaya N, Yuan C, Chu B, et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation 2005; 111: 2768-2775.
40. Zhao XQ, Dong L, Hatsukami T, et al. MR imaging of carotid plaque composition during lipid-lowering therapy: a prospective assessment of effect and time course. JACC Cardiovasc Imaging 2011; 4: 977-986.
41. Hatsukami TS, Ross R, Polissar NL, et al. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation 2000; 102: 959-964.
42. Rudd JH, Hyafil F, Fayad ZA., Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 1009-1016.
43. Briley-Saebo KC, Mulder WJ, Mani V, et al. Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes. J Magn Reson Imaging 2007; 26: 460-479.
44. Libby P., Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.
45. Von Zur Muhlen C, von Elverfeldt D, Bassler N, et al. Superparamagnetic iron oxide binding and uptake as imaged by magnetic resonance is mediated by the integrin receptor Mac-1 (CD11b/CD18): implications on imaging of atherosclerotic plaques. Atherosclerosis 2007; 193: 102-111.
46. Raynal I, Prigent P, Peyramaure S, et al. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004; 39: 56-63.
47. Litovsky S, Madjid M, Zarrabi A, et al. Superparamagnetic iron oxide-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tissue necrosis factor-α, interleukin-1β, and interferon-γ. Circulation 2003; 107: 1545-1549.
48. Yancy AD, Olzinski AR, Hu TC, et al. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling. J Magn Reson Imaging 2005; 21: 432-442.
49. Ruehm SG, Corot C, Vogt P, et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001; 103: 415-422.
50. Hyafil F, Laissy JP, Mazighi M, et al. Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta: relationship between signal loss and macrophage infiltration. Arterioscler Thromb Vasc Biol 2006; 26: 176-181.
51. Morris JB, Olzinski AR, Bernard RE, et al. p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler Thromb Vasc Biol 2008; 28: 265-271.
52. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003; 107: 2453-2458.
53. Trivedi RA, Mallawarachi C, U-King-Im JM, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol 2006; 26: 1601-1606.
54. Trivedi RA, U-King-Im JM, Graves MJ, et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 2004; 35: 1631-1635.
55. Tang TY, Howarth SP, Miller SR, et al. for the ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009; 53: 2039-2050.
56. Briley-Saebo KC, Mani V, Hyafil F, et al. Fractionated Feridex and positive contrast: in vivo MR imaging of atherosclerosis. Magn Reson Med 2008; 59: 721-730.
57. Korosoglou G, Weiss RG, Kedziorek DA, et al. Noninvasive detection of macrophage-rich atherosclerotic plaque in hyperlipidemic rabbits using "positive contrast" magnetic resonance imaging. J Am Coll Cardiol 2008; 52: 483-491.
58. Moreno PR, Purushothaman KR, Zias E, et al. Neovascularization in human atherosclerosis. Curr Mol Med 2006; 6: 457-477.
59. Tenaglia AN, Peters KG, Sketch MH Jr, et al. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J 1998; 135: 10-14.
60. Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004; 110: 2032-2038.
61. Moulton KS., Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep 2001; 3: 225-233.
62. Doyle B, Caplice N., Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 2007; 49: 2073-2080.
63. Leclercq A, Houard X, Philippe M, et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol 2007; 82: 1420-1429.
64. Lappalainen H, Laine P, Pentikainen MO, et al. Mast cells in neovascularized human coronary plaques store and secrete basic fibroblast growth factor, a potent angiogenic mediator. Arterioscler Thromb Vasc Biol 2004; 24: 1880-1885.
65. Padhani AR., Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002; 16: 407-422.
66. Kerwin W, Hooker A, Spilker M, et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 2003; 107: 851-856.
67. Dong L, Kerwin WS, Chen H, et al. Carotid artery atherosclerosis: effect of intensive lipid therapy on the vasa vasorum-evaluation by using dynamic contrast-enhanced MR imaging. Radiology 2011; 260: 224-231.
68. Calcagno C, Cornily JC, Hyafil F, et al. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler Thromb Vasc Biol 2008; 28: 1311-1317.
69. Calcagno C, Vucic E, Mani V, et al. Reproducibility of black blood dynamic contrast-enhanced magnetic resonance imaging in aortic plaques of atherosclerotic rabbits. J Magn Reson Imaging 2010; 32: 191-198.
70. Vucic E, Dickson SD, Calcagno C, et al. Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc Imaging 2011; 4: 1100-1109.
71. Cornily JC, Hyafil F, Calcagno C, et al. Evaluation of neovessels in atherosclerotic plaques of rabbits using an albumin-binding intravascular contrast agent and MRI. J Magn Reson Imaging 2008; 27: 1406-1411.
72. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
73. Galis ZS, Khatri JJ., Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262.
74. Lancelot E, Amirbekian V, Brigger I, et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol 2008; 28: 425-432.
75. Amirbekian V, Aguinaldo JG, Amirbekian S, et al. Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology 2009; 251: 429-438.
76. Hyafil F, Vucic E, Cornily JC, et al. Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases. Eur Heart J 2011; 32: 1561-1571.
77. Schrigten D, Breyholz HJ, Wagner S, et al. A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography. J Med Chem 2012; 55: 223-232.
78. Yun M, Jang S, Cucchiara A, et al. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med 2002; 32: 70-76.
79. Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 2007; 49: 1533-1539.
80. Tahara N, Kai H, Nakaura H, et al. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose positron emission tomography. Eur Heart J 2007; 28: 2243-2248.
81. Rudd J, Warburton E, Fryer T, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxy glucose positron emission tomography. Circulation 2002; 105: 2708-2711.
82. Hyafil F, Cornily JC, Rudd JH, et al. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med 2009; 50: 959-965.
83. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006; 48: 1818-1824.
84. Bucerius J, Duivenvoorden R, Mani V, et al. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC Cardiovasc Imaging 2011; 4: 1195-1205.
85. Bucerius J, Mani V, Moncrieff C, et al. Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol 2012; 59: 2080-2088.
86. Aziz K, Berger K, Claycombe K, et al. Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation 2008; 117: 2061-2070.
87. Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol 2008; 15: 209-217.
88. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006; 48: 1825-1831.
89. Lee SJ, On YK, Lee EJ, et al. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med 2008; 49: 1277-1282.
90. Williams G, Kolodny GM., Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol 2008; 190: W151-W156.
91. Maschauer S, Prante O, Hoffmann M, et al. Characterization of 18F-FDG uptake in human endothelial cells in vitro. J Nucl Med 2004; 45: 455-460.
92. Ishimori T, Saga T, Mamede M, et al. Increased (18)F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med 2002; 43: 658-663.
93. Dweck MR, Chow MW, Joshi NV, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol 2012; 59: 1539-1548.
94. Rominger A, Saam T, Vogl E, et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med 2010; 51: 193-197.
95. Dobrucki LW, Sinusas AJ., PET and SPECT in cardiovascular molecular imaging. Nat Rev Cardiol 2010; 7: 38-47.
96. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 2008; 14: 459-465.
97. Mizoguchi M, Tahara N, Tahara A, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes: a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 2011; 4: 1110-1118.
98. Gaemperli O, Shalhoub J, Owen DR, et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J 2012; 33: 1902-1910.
99. Majmudar MD, Nahrendorf M., Cardiovascular molecular imaging: the road ahead. J Nucl Med 2012; 53: 673-676.